Computer-designed miniproteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19. The lead antiviral candidate rivals the best-known SARS-CoV-2 monoclonal antibodies in its protective actions. The synthetic antiviral candidates were designed to prevent infection by interfering with the mechanism that coronaviruses use to break into and enter cells.